PRECISION GENOMIC TESTING
Dedicated to molecular discovery
DxTerity® provides leading solutions for genomic profiling of immune response. Next Generation Sequencing is conducted on both Illumina and Ion Torrent NGS platforms and clinical results are delivered using the DxDirect® low-cost platform. Our experienced scientific team can help provide insight into the genomic data.
Discovery to Clinical Support
DxTerity has expertise in all stages of the discovery, development and clinical validation process. Initial discovery begins with transcriptome-level analysis followed by by 100 to 1,000 gene targeted panels for cohort analysis and eventually low-cost, DxDirect clinical assay for routine delivery.
DxTerity offers the flexibility of using different technology platforms coupled with focused panels, proprietary assays and custom, exploratory assays to meet a variety of clinical trial requirements. Our bioinformatic-driven, progressive targeting approach ensures quality development outcomes for exploration, research assays and clinical trial assays. Services also include:
- Whole Transcriptome
- T-Cell Immune Repertoire
- Targeted Pathway Panels
- DxDirect® High-Throughput Multiplexed Assays
High Throughput Clinical Quality
DxTerity has extensive experience with molecular analysis and multiplex testing methods. We support early validation pathways through lab developed tests for clinically relevant assays. Our focus on affordable testing emphasizes high throughput, low cost assays. This approach sets the stage for full in-vitro diagnostic FDA test development for monitoring and disease activity testing.
Licensed, certified and accredited
Maintaining high standards is a core tenet of DxTerity’s commitment to quality. We maintain a Quality Management System that is ISO 13845 certified. Our clinical diagnostic laboratory is College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified licensed.